Skip to main content
Premium Trial:

Request an Annual Quote

Twist Bioscience Providing Antibody Optimization to Pandion Therapeutics for Drug Development

NEW YORK (GenomeWeb) – Twist Bioscience and Pandion Therapeutics plan to use Twist's antibody optimization platform to develop therapeutics for autoimmune and inflammatory disease, the companies said today.

The firms did not disclose financial details of the agreement.

Twist "has a highly differentiated capability to optimize antibodies for many attributes including affinity, expression, solubility, half-life, immunogenicity, druggability, and processability," Anthony Coyle, co-founder and CEO of Pandion, said in a statement.

The antibody optimization platform makes use of Twist's high-throughput oligonucleotide synthesis technology to generate an antibody library.

Pandion is a Cambridge, Massachusetts-based biotech company that was founded in 2017 and is focused on developing a pipeline of antibody therapeutics.

Last week, Twist announced a separate strategic collaboration with LakePharma, a contract research, development and manufacturing organization (CRDMO) for biologics, to offer antibody discovery and development services to pharmaceutical and biotech customers.

Under the terms of that deal, LakePharma will offer Twist's antibody optimization platform as a service to its customers while Twist will have access to LakePharma's discovery and development services.

Aside from its collaborations with Pandion and LakePharma, Twist is also working with Vanderbilt University Medical Center to discover and design antibody therapeutics against potential pandemics such as Zika virus.

Early this year, Twist CEO Emily Leproust said that drug discovery, harnessing its ability to make large antibody libraries, would be a focus of the company.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.